This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ChemoCentryx Past Earnings Performance

Past criteria checks 0/6

Key information

-47.2%

Earnings growth rate

-40.7%

EPS growth rate

Biotechs Industry Growth	-14.6%
Revenue growth rate	-9.5%
Return on equity	-56.3%
Net Margin	-357.0%
Last Earnings Update	30 Jun 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How ChemoCentryx makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:2CX Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses
30 Jun 22	37	-133	97
31 Mar 22	27	-141	89
31 Dec 21	32	-132	79
30 Sep 21	34	-121	68
30 Jun 21	22	-123	59
31 Mar 21	69	-63	50
31 Dec 20	65	-55	42
30 Sep 20	71	-41	36
30 Jun 20	76	-30	32
31 Mar 20	34	-65	27
31 Dec 19	36	-55	24
30 Sep 19	35	-51	23
30 Jun 19	34	-49	22
31 Mar 19	42	-40	21
31 Dec 18	43	-38	20
30 Sep 18	90	12	19
30 Jun 18	90	17	17
31 Mar 18	84	14	17
31 Dec 17	82	18	17
30 Sep 17	31	-29	16
30 Jun 17	26	-30	16
31 Mar 17	20	-31	15
31 Dec 16	12	-40	15
30 Sep 16	7	-44	15
30 Jun 16	3	-48	15
31 Mar 16	0	-51	15

Quality Earnings: 2CX is currently unprofitable.

Growing Profit Margin: 2CX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 2CX is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.

Accelerating Growth: Unable to compare 2CX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2CX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-17.4%).

Return on Equity

High ROE: 2CX has a negative Return on Equity (-56.27%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

ChemoCentryx Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

Recent updates

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of ChemoCentryx, Inc. (NasdaqGS:CCXI) from a group of shareholders.

Chemocentryx, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.44 loss per share (vs US$0.56 loss in 2Q 2021)

Amgen Inc. (NasdaqGS:AMGN) entered into a definitive agreement to acquire ChemoCentryx, Inc. (NasdaqGS:CCXI) for $3.7 billion.

ChemoCentryx, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Chemocentryx, Inc. Announces Appointment of Jennifer L. Herron to Board as Independent Director

ChemoCentryx, Inc. Appoints Yi Ching Yau as Senior Vice President, Finance and Principal Accounting Officer

Chemocentryx Inc. Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered Pd-L1 Inhibitor, Ccx559, At the 2022 American Society of Clinical Oncology (Asco) Annual Meeting

ChemoCentryx Announces Changes to its Board of Directors

First quarter 2022 earnings released: US$0.55 loss per share (vs US$0.43 loss in 1Q 2021)

Insufficient new directors

ChemoCentryx, Inc. Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, Ccx559, At American Association for Cancer Research (Aacr) Annual Meeting 2022

ChemoCentryx, Inc., Annual General Meeting, May 26, 2022

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

ChemoCentryx, Inc. to Report Q4, 2021 Results on Mar 01, 2022

ChemoCentryx, Inc Announces EU Approval of Tavneos® (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.35 loss in 3Q 2020)

ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated Vasculitis

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.32 profit in 2Q 2020)

Rosen Law Firm Encourages ChemoCentryx, Inc. Investors with Losses to Secure Counsel Before Important July 6, 2021 Deadline in Securities Class Action

Kessler Topaz Meltzer & Check, LLP Announces Securities Fraud Class Action Lawsuit Filed against ChemoCentryx, Inc

Executive VP & COO recently bought €99k worth of stock

ChemoCentryx Announces Results of U.S. Food and Drug Administration Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against ChemoCentryx, Inc

First quarter 2021 earnings released: US$0.43 loss per share (vs US$0.35 loss in 1Q 2020)

Director recently sold €1.5m worth of stock

ChemoCentryx, Inc Appoint Susan M. Kanaya to the Board of Directors

ChemoCentryx, Inc. Appoints Tausif Butt as Executive Vice President and Chief Operating Officer

Full year 2020 earnings released: US$0.84 loss per share (vs US$0.97 loss in FY 2019)

Revenue misses expectations

Chemocentryx Appoints Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer

ChemoCentryx, Inc. to Report Q4, 2020 Results on Mar 01, 2021

ChemoCentryx Announces Publication in the New England Journal of Medicine of Results of the Pivotal Phase III Advocate Trial of Avacopan for the Treatment of Anca-Associated Vasculitis

New 90-day high: €54.18

Independent Director recently sold €1.0m worth of stock

Independent Director recently sold €1.3m worth of stock

ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate

New 90-day high: €49.12

New 90-day high: €47.85

New 90-day high: €47.06

Third quarter 2020 earnings released: US$0.35 loss per share

Revenue misses expectations

ChemoCentryx, Inc. to Report Q3, 2020 Results on Nov 09, 2020

ChemoCentryx, Inc. Announces Positive Topline Results of Phase II Aurora Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

ChemoCentryx, Inc. Announces FDA Acceptance of the Avacopan New Drug Application for the Treatment of ANCA-Associated Vasculitis

New 90-day low - €42.71

First half earnings released

ChemoCentryx, Inc. to Report Q2, 2020 Results on Aug 10, 2020

ChemoCentryx, Inc.(NasdaqGS:CCXI) dropped from Russell Microcap Index

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta